Literature DB >> 24485408

Is elevated norepinephrine an etiological factor in some cases of schizophrenia?

Paul J Fitzgerald1.   

Abstract

A number of hypotheses have been put forth regarding the etiology of schizophrenia, including the dopamine hypothesis, NMDA receptor hypofunction hypothesis, and others. A lesser known theory is that elevated noradrenergic signaling plays a causative role in the disease. This paper briefly re-examines the merits of this hypothesis, including as it relates to some recently published studies. Several lines of evidence are investigated, including: endogenous level studies of norepinephrine (NE); modulation of the disease by noradrenergic drugs; association of the disease with bipolar disorder and hypertension, since these latter two conditions may involve elevated NE transmission; and effects of psychological stress on the disease, since stress can produce elevated release of NE. For many of these lines of evidence, their relationship with prepulse inhibition of startle is examined. A number of these studies support the hypothesis, and several suggest that elevated NE signaling plays a particularly prominent role in the paranoid subtype of schizophrenia. If the hypothesis is correct for some persons, conventional pharmaceutical treatment options, such as use of atypical antipsychotics (which may themselves modulate noradrenergic signaling), may be improved if selective NE transmission modulating agents are added to or even substituted for these conventional drugs.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clonidine; Desipramine; Guanfacine; Paranoid schizophrenia; Prazosin; Propranolol; Yohimbine

Mesh:

Substances:

Year:  2014        PMID: 24485408     DOI: 10.1016/j.psychres.2014.01.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  Activation of brainstem and midbrain nuclei during cognitive control in medicated patients with schizophrenia.

Authors:  Stefanie Köhler; Gerd Wagner; Karl-Jürgen Bär
Journal:  Hum Brain Mapp       Date:  2018-09-05       Impact factor: 5.038

2.  Role of Norepinephrine in Schizophrenia: An Old Theory Applied to a New Case in Emergency Medicine.

Authors:  Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2020-07-01

3.  The catecholaminergic neurotransmitter system in methylmercury-induced neurotoxicity.

Authors:  Marcelo Farina; Michael Aschner; João Batista Teixeira da Rocha
Journal:  Adv Neurotoxicol       Date:  2017-09-01

4.  Demographic, clinical and social characteristics of forensic patients diagnosed with schizophrenia at the Free State Psychiatric Complex, Bloemfontein, South Africa.

Authors:  Nkomile Ntswaki Clourinah Setlaba; Nathaniel Lehlohonolo Mosotho; Gina Joubert
Journal:  Psychiatr Psychol Law       Date:  2020-03-13

5.  Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects.

Authors:  Coraline D Metzger; Maike Wiegers; Martin Walter; Birgit Abler; Heiko Graf
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-25       Impact factor: 5.176

Review 6.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

7.  Clozapine, chlorpromazine and risperidone dose-dependently reduce emotional hyperthermia, a biological marker of salience.

Authors:  William W Blessing; Esther M Blessing; Mazher Mohammed; Youichirou Ootsuka
Journal:  Psychopharmacology (Berl)       Date:  2017-08-15       Impact factor: 4.530

Review 8.  Current Understanding of the Neurobiology of Agitation.

Authors:  Christopher W T Miller; Vedrana Hodzic; Eric Weintraub
Journal:  West J Emerg Med       Date:  2020-07-02

9.  Locus Ceruleus Norepinephrine Release: A Central Regulator of CNS Spatio-Temporal Activation?

Authors:  Marco Atzori; Roberto Cuevas-Olguin; Eric Esquivel-Rendon; Francisco Garcia-Oscos; Roberto C Salgado-Delgado; Nadia Saderi; Marcela Miranda-Morales; Mario Treviño; Juan C Pineda; Humberto Salgado
Journal:  Front Synaptic Neurosci       Date:  2016-08-26

10.  Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects.

Authors:  Magdalena Białoń; Marcelina Żarnowska; Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik
Journal:  Psychopharmacology (Berl)       Date:  2020-02-20       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.